Can We Effectively Target FGFR with the Novel Agent Erdafitinib for Muscle-Invasive Bladder Cancer? Highlights from ASCO 2018 (BMIC-050)

Can We Effectively Target FGFR with the Novel Agent Erdafitinib for Muscle-Invasive Bladder Cancer? Highlights from ASCO 2018 (BMIC-050)

User Photo
BeaconMedIC

2 years
100 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Dr. Daniel Goldstein reviews highlights in bladder cancer from ASCO 2018, including the novel agent erdafitinib as a treatment targeting fibroblast growth factor receptor (FGFR) alterations in muscle-invasive, advanced bladder cancer.
Up Next Autoplay